Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This study will compare the effectiveness of osimertinib alone with the combination of
osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung
cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual
treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to
osimertinib could possibly add to the anticancer effects of the usual treatment and help stop
cancer from growing or spreading.